As of December 01. 2016, there have been 698 (695 MS, 3 CD) confirmed PML cases worldwide.
As of November 30, 2016, overall PML incidence: 4.18 per 1000 patients (95% CI 3.88 to 4.51 per 1000 patients). 23% of patients have died; 77% of patients are alive with varying levels of disability.
As of September 30, 2016, approximately 161,300 patients received natalizumab in post-marketing setting worldwide.
After the re-approval of Tysabri® (Natalizumab), there were the expected/feared PML disorders. I have generated a table with the main available data from June 2008 to june 2016.
I would be grateful for additional information via comment or e-mail. Tysabri®, Avonex®, Rebif® & Copaxone® are trademarks.